Client-Tailored Solutions
We have tools to inform whatever R&D decisions you’re facing in any stage of development, including: setting indication priorities, advising on go/no-go decisions, assessing market access and pricing potential, share forecasting, and patient flow modeling. We can help you find the answers you need.
Tools for BD & Early R&D
Disease Area Scan
Our “Disease Area Scan” tools help clients who don’t yet have TPPs for their asset find the indications that present the best opportunities. We begin by characterizing each population’s unmet medical need, population size, and competitive intensity. After identifying the indications that appear attractive from this assessment, we use heat maps to convey what levels of improvement in efficacy and safety will correspond to certain levels of clinical innovation and patient-share potential. These heat maps can streamline the TPP building process.
Indication Prioritization
Our “Indication Prioritization” tools can help clients with assets that are suited for a range of indications decide which of those indications they should focus on for initial approval. We provide a variety of comparative views that characterize the asset across the populations by its unmet medical need, population size, competitive intensity, and Clinical Innovation vs. the standard of care. This process not only helps the client to choose which indications they will target, but the sequencing as well.
Disease Target Assessment
Disease Target Assessment (DTA) estimates an asset’s commercial performance given uncertainty about its clinical attributes. Our DTAs help early development teams understand the peak-year patient share that they can expect their asset to achieve. This output is driven by the clinical benefit offered by the asset vs. the SOC, its relative cost, as well as the competitive environment and epidemiology.
Tools for Late Stage Development
Patient Share Forecasting
For teams in late-stage development, we seamlessly integrate our Competition Module with our DTA technology to forecast patient share over time. Our forecasting models instantly revise patient share and revenue predictions when fresh information arises about an asset’s clinical attributes and launch date, or as new information emerges about competitors — allowing teams to quickly and authoritatively answer management questions about the impact of events.
Epidemiology and Patient Flow Modelling
To support revenue projections, we have well-researched, sourced, and carefully calibrated epidemiology estimates in all our DTA and forecast models. In addition, we also offer incidence-based patient flow models that accurately estimate the number of patients available for treatment at each stage of disease and line of treatment.
Market access
Our market access analytics can be used for both early and late phase agents. We compare the clinical benefit of the drug to its cost, and benchmark those results to a historical data set of launched drugs to identify appropriate analogs. Our clinical benefit vs. cost metric is strongly predictive of the pricing and market access outlook for new agents. We also have distinctive tools for both early- and late-stage oncology as well as rare diseases.
